Home » Stocks » PHGE

BiomX, Inc. (PHGE)

Stock Price: $6.28 USD -0.11 (-1.72%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
Market Cap 151.56M
Revenue (ttm) n/a
Net Income (ttm) -30.09M
Shares Out 24.25M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $6.28
Previous Close $6.39
Change ($) -0.11
Change (%) -1.72%
Day's Open 6.41
Day's Range 6.20 - 6.41
Day's Volume 7,401
52-Week Range 4.52 - 9.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target s...

2 weeks ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing natural and engineered phage therapies that target specifi...

3 weeks ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today ann...

1 month ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today ann...

1 month ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announce...

2 months ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced ...

3 months ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced ...

4 months ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced ...

5 months ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today reported f...

5 months ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced ...

5 months ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announce...

5 months ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announce...

5 months ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announce...

6 months ago - Business Wire

BiomX is focused on large market opportunities using the unique approach of manipulating the microbiome utilizing phage therapy.

6 months ago - Seeking Alpha

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today reported financia...

8 months ago - Business Wire

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced th...

8 months ago - Business Wire

Forget traditional IPOs! This blank check vehicle is proving to be an effective tool for biotech companies to raise capital.

Other stocks mentioned: IMVT, TXAC
8 months ago - The Motley Fool

About PHGE

BiomX Inc., a clinical stage company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's lead product candidate BX001, which is in phase II that helps to modify the appearance of skin in various skin types, including oily and acne... [Read more...]

Industry
Biotechnology
Founded
2015
Stock Exchange
NYSEAMERICAN
Ticker Symbol
PHGE
Full Company Profile

Financial Performance

Financial Statements